4.8 Review

Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine

期刊

SCIENCE ADVANCES
卷 1, 期 7, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.1500439

关键词

-

资金

  1. National Science Foundation [CMMI-1350197, CMMI-0856492, DMR-1343991, IIA-1444100]
  2. Center for Scalable and Integrated NanoManufacturing [DMI-0327077]
  3. V Foundation for Cancer Research Scholars Award
  4. Wallace H. Coulter Foundation
  5. National Cancer Institute [U54CA151880]
  6. Society for Laboratory Automation and Screening Endowed Fellowship
  7. Beckman Coulter Life Sciences
  8. American Academy of Implant Dentistry Research Foundation [20150460]
  9. National Research Foundation Cancer Science Institute of Singapore RCE
  10. National Medical Research Council [NMRC CBRGNIG NMRC/BNIG/2012/2013]
  11. Ministry of Education Academic Research Fund [MOE AcRF Tier 1 T1, T1-BSRG]
  12. Yong Loo Lin Trust
  13. NATIONAL CANCER INSTITUTE [U54CA151880] Funding Source: NIH RePORTER
  14. Direct For Mathematical & Physical Scien [1343991] Funding Source: National Science Foundation
  15. Office Of Internatl Science &Engineering [1444100] Funding Source: National Science Foundation

向作者/读者索取更多资源

The implementation of nanomedicine in cellular, preclinical, and clinical studies has led to exciting advances ranging from fundamental to translational, particularly in the field of cancer. Many of the current barriers in cancer treatment are being successfully addressed using nanotechnology-modified compounds. These barriers include drug resistance leading to suboptimal intratumoral retention, poor circulation times resulting in decreased efficacy, and off-target toxicity, among others. The first clinical nanomedicine advances to overcome these issues were based on monotherapy, where small-molecule and nucleic acid delivery demonstrated substantial improvements over unmodified drug administration. Recent preclinical studies have shown that combination nanotherapies, composed of either multiple classes of nanomaterials or a single nanoplatform functionalized with several therapeutic agents, can image and treat tumors with improved efficacy over single-compound delivery. Among the many promising nanomaterials that are being developed, nanodiamonds have received increasing attention because of the unique chemical-mechanical properties on their faceted surfaces. More recently, nanodiamond-based drug delivery has been included in the rational and systematic design of optimal therapeutic combinations using an implicitly de-risked drug development platform technology, termed Phenotypic Personalized Medicine-Drug Development (PPM-DD). The application of PPM-DD to rapidly identify globally optimized drug combinations successfully addressed a pervasive challenge confronting all aspects of drug development, both nano and non-nano. This review will examine various nanomaterials and the use of PPM-DD to optimize the efficacy and safety of current and future cancer treatment. How this platform can accelerate combinatorial nanomedicine and the broader pharmaceutical industry toward unprecedented clinical impact will also be discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据